UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) ~~October~~April 1024, ~~2011~~2012

Calypte Biomedical Corporation

(Exact name of Company as specified in its charter)

Delaware	000-20985	06-1226727
(State or Other Jurisdiction)	(Commission File Number)	(I.R.S. Employer Identification)
of Incorporation)

15875 SW 72nd Ave, Portland, OR 97224

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (503) 726-2227

~~16290 S.W. Upper Boones Ferry Road, Portland, OR 97224~~N/A

(Former name or former address, if changed since last report)

o	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 40.13e-4(c))

~~Item~~ITEM 15.~~01 Entry~~02 Departure ~~into~~of aDirectors ~~Material~~or ~~Definitive~~Principal ~~Agreement~~Officers; Election of Directors; Appointment of Principal Officers

~~The~~(c) On ~~Registrant~~April ~~and~~24, ~~David~~2012, ~~Khidasheli~~Kartlos ~~have~~Edilashvili, ~~entered~~a ~~into~~member aof ~~Memorandum~~the registrant’s Board of ~~Understanding~~Directors, ~~dated~~was ~~October~~elected 10as the Chief Financial Officer and Secretary of the registrant, ~~2011~~replacing (Adel Karas, who will continue as the ~~“MOU”)~~registrant’s ~~pursuant~~Chairman toof ~~which~~the ~~Mr.~~Board ~~Khidasheli~~of ~~has~~Directors, ~~agreed~~President toand ~~invest~~Chief Executive Officer. Mr. Edilashvili will receive a ~~total~~salary of $1~~,000,000~~.00 per year in ~~the~~his ~~Registrant~~position. ~~The~~Mr. ~~investment~~Edilashvili ~~will~~has ~~consist~~served ofas a ~~series~~Vice President of ~~advances~~the toregistrant, ~~the~~currently ~~Registrant~~based ~~pursuant~~in toDubai, aU.A.E. ~~schedule~~and topreviously bein ~~determined~~Geneva, bySwitzerland, ~~the~~since ~~parties~~August ~~within~~2007. 30From ~~days~~2005 ~~following~~to ~~the~~2007 ~~execution~~he was a Senior Technical Advisor of ~~the~~WAPMERR ~~MOU~~in Geneva. ~~The~~Prior ~~first~~thereto, ~~such~~he ~~advance,~~served inas First Secretary for the ~~amount~~Embassy of ~~$50,000,~~Georgia ~~was~~in ~~made~~Geneva. onMr. ~~October~~Edilashvili holds ~~10,~~an ~~2011~~MA in finances from Tbilisi State University in Georgia.

The Registrant expects that such advances will eventually be converted to Common Stock. During 2010 Mr. Khidasheli made a total of $500,000 in advances to the Registrant, which were converted to Common Stock at a rate of one share for every $0.03 advanced. The Company and Mr. Khidasheli have not entered into a definitive agreement under which Mr. Khidasheli’s advances will be converted to stock. Until such agreement is entered into, Mr. Khidasheli’s advances will represent debt obligations on the part of the Registrant.

A copy of the Registrant’s press release relating to the MOU is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press release issued by the Registrant on October 14, 2011

SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the ~~Registrant~~registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: ~~October~~April 1427, ~~2011~~2012

	Calypte Biomedical Corporation



	By:	/s/ Adel Karas
		Adel Karas
		President and Chief Executive Officer

Filing Compare · CALYPTE BIOMEDICAL CORP